Cargando…

Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa®)

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Clinics Cardive Publishing 2010
Materias:	Cardiovascular Topics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592318/ https://www.ncbi.nlm.nih.gov/pubmed/20532462

Ejemplares similares

Boehringer Ingelheim and Eli Lilly and Company announces trategic alliance to bring new diabetes treatments to patients worldwide
Publicado: (2011)

What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®))
por: Dwyer, Christopher Michael, et al.
Publicado: (2015)

South African experts comment on FDA approval of dabigatran inatrial fibrillation
por: E, Klug, et al.
Publicado: (2011)

Smartphone apps launched for atrial fibrillation patients and their healthcare providers
Publicado: (2018)

Hemoclot Thrombin Inhibitor Assay and Expected Peak-Trough Levels of Dabigatran: A Multicenter Study
por: Liu, Zhiyan, et al.
Publicado: (2022)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

Alzheimer’s Disease—Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran
por: Grossmann, Klaus
Publicado: (2021)

Smartphone app directs first responders to cardiac arrest three minutes before ambulance
Publicado: (2018)

Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations
por: Xu, Xiaoping, et al.
Publicado: (2019)

Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia
por: Mirdamadi, Ahmad
Publicado: (2013)

Multicentre evaluation of the Boehringer Mannheim/Hitachi 911 Analysis System
por: Zaman, Z., et al.
Publicado: (1993)

Multicentre evaluation of the Boehringer Mannheim/Hitachi 917 analysis system
por: van Suijlen, Jeroen D. E., et al.
Publicado: (2000)

Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function
por: Yeh, Calvin H., et al.
Publicado: (2016)

The Epidemiological Boehringer Ingelheim Employee Study (Part 3): Association of Elevated Fasting Insulin Levels but Not HOMA-IR With Increased Intima Media Thickness and Arteriosclerosis in Middle-Aged Persons
por: Röhling, Martin, et al.
Publicado: (2021)

Idarucizumab (Praxbind) for Reversal of Pradaxa Prior to Emergent Repair of Contained Ruptured Transverse Arch Aneurysm
por: Belli, Erol Vahit, et al.
Publicado: (2017)

Xanthine oxidase inhibitors in ischaemic heart disease
por: Zdrenghea, Mihnea, et al.
Publicado: (2017)

Chronic heart failure treatment benefits from pro-BNP-directed therapy
por: J, Aalbers
Publicado: (2011)

Dabigatran for left atrial thrombus
por: Morita, Sae, et al.
Publicado: (2013)

New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders
por: Dahl, Ola E
Publicado: (2012)

The effect of the first office blood pressure reading on hypertension-related clinical decisions
por: Oladipo, Idris, et al.
Publicado: (2012)

Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation
por: Huber, K, et al.
Publicado: (2013)

Oscillometric blood pressure reference values of African full-term neonates in their first days postpartum
por: Sadoh, Wilson E, et al.
Publicado: (2009)

Robotically controlled ablation for atrial fibrillation: the first real-world experience in Africa with the Hansen robotic system
por: Lorgat, Faizel, et al.
Publicado: (2012)

First reported cases: renal denervation with secondgeneration multi-electrode catheter via brachial and radial access
por: Heradien, MJ, et al.
Publicado: (2016)

VI Scandinavian COPD Research Symposium Published with support from Boehringer Ingelheim
Publicado: (2015)

In-hospital and mid-term adverse clinical outcomes of a direct stenting strategy versus stenting after predilatation for the treatment of coronary artery lesions
por: Alidoosti, M, et al.
Publicado: (2008)

Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice
por: Pingel, Simon, et al.
Publicado: (2014)

The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency
por: Gribkova, Irina V., et al.
Publicado: (2016)

Familial clustering of risk factors for cardiovascular disease among first-degree relatives of patients with chronic kidney disease in a sub-Saharan African population
por: Raji, Yemi, et al.
Publicado: (2015)

Ximelagatran: Direct Thrombin Inhibitor
por: Ho, Shir-Jing, et al.
Publicado: (2006)

Data regarding the effects of thrombin and dabigatran-inhibited thrombin on protease-activated receptor 1 and activation of human atrial fibroblasts
por: Altieri, Paola, et al.
Publicado: (2018)

Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway
por: Ewees, Mohamed Gamal El-Din, et al.
Publicado: (2021)

Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay
por: Carlo, Audrey, et al.
Publicado: (2022)

Patient Characteristics and Clinical Outcomes with Low-Dose Dabigatran
por: Ebrahimi, Ramin, et al.
Publicado: (2017)

The Epidemiological Boehringer Ingelheim Employee Study—Part I: Impact of Overweight and Obesity on Cardiometabolic Risk
por: Kempf, Kerstin, et al.
Publicado: (2013)

Editorial: Advances in thrombin generation
por: de Laat-Kremers, Romy, et al.
Publicado: (2023)

Reversible covalent direct thrombin inhibitors
por: Sivaraja, Mohanram, et al.
Publicado: (2018)

Direct Thrombin Inhibitor Dabigatran Compromises Pulmonary Endothelial Integrity in a Murine Model of Breast Cancer Metastasis to the Lungs; the Role of Platelets and Inflammation-Associated Haemostasis
por: Smeda, Marta, et al.
Publicado: (2022)

Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay
por: Artang, Ramin, et al.
Publicado: (2017)

Improved efficacy/safety profile of factor XIa inhibitor BMS‐724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys
por: Wong, Pancras C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jusa6bot4gigv1l6gdn3goj5an